바이오의약품 CMO 및 CRO 시장 규모, 점유율, 성장 분석 : 공급원별, 서비스 유형별, 제품별, 지역별 - 업계 예측(2026-2033년)

Biopharmaceutical CMO & CRO Market size was valued at USD 34.31 Billion in 2024 and is poised to grow from USD 36.34 Billion in 2025 to USD 57.48 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The biopharmaceutical industry is witnessing significant growth, driven by increasing consumer demand for innovative therapies. Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) have become pivotal in supporting pharmaceutical companies by providing outsourced manufacturing and comprehensive research services, respectively. This trend highlights a shift toward outsourcing resource-intensive processes, including entire biomanufacturing chains, enhancing the demand for contract-based services. The integration of bioprocessing capabilities through mergers and acquisitions allows CMOs to offer streamlined solutions, facilitating accelerated product launches. Investments in integrated manufacturing further bolster this sector, as evidenced by strategic partnerships aimed at improving productivity and efficiency. Overall, CMOs and CROs play a crucial role in the biopharmaceutical landscape, representing over 20% of the pharmaceutical market globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biopharmaceutical CMO & CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biopharmaceutical CMO & CRO Market Segments Analysis

Global Biopharmaceutical CMO and CRO Market is segmented by Source, Service Type, Product and region. Based on Source, the market is segmented into Mammalian and Non-mammalian. Based on Service Type, the market is segmented into Contract Manufacturing and Contract Research. Based on Product, the market is segmented into Biologics and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical industry has experienced a wave of consolidations aimed at enhancing competitiveness and expanding operations within the contract manufacturing and service sectors. As new therapies and innovative bioprocessing techniques emerge, contract bioproducers face mounting pressures to adapt to these changes in market dynamics. To address the diverse needs of stakeholders and consumers, alternative business models are becoming more prevalent. Additionally, the implementation of single-use systems in manufacturing facilities is expected to significantly enhance production capacity. Collectively, these factors indicate strong growth potential for the biopharmaceutical CMO and CRO market, offering new opportunities in the global landscape.

Restraints in the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market faces several constraints that hinder its growth potential, despite the lucrative profit margins it offers compared to the pharmaceutical CMO sector. A primary challenge lies in the significant investments required for manufacturing facilities and advanced equipment to accelerate biomanufacturing processes. Additionally, many established biopharmaceutical companies are hesitant to fully embrace outsourcing, further limiting market expansion. Moreover, negotiations between CMOs and clients can be complicated due to the intricate regulatory environment and the complexity inherent in these services. Issues surrounding intellectual property rights, confidentiality, and warranties add to the difficulties in client-CMO agreements, creating further barriers to market growth.

Market Trends of the Biopharmaceutical CMO & CRO Market

The biopharmaceutical CMO and CRO market is experiencing a significant upward trend driven by an intensified focus on new product development, expanded R&D activities, and strategic collaborations. As companies face challenges in R&D efficiency and escalating development costs, CMOs and CROs are emerging as pivotal partners, facilitating faster commercial operations. Growth strategies such as geographical expansions, mergers and acquisitions, and enhanced distribution networks are becoming integral to gaining competitive advantages. This evolving landscape underscores the increasing reliance on contract organizations by biopharmaceutical firms, paving the way for sustained market growth and innovation in the biopharmaceutical sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Biopharmaceutical CMO & CRO Market Size by Source & CAGR (2026-2033)

• Market Overview
• Mammalian
• Non-mammalian

Global Biopharmaceutical CMO & CRO Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Contract Manufacturing
  • Process Development
  • Downstream
  • Upstream
  • Fill & Finish Operations
  • Analytical & QC Studies
  • Packaging
• Contract Research
  • Oncology
  • Inflammation & Immunology
  • Cardiology
  • Neuroscience
  • Others

Global Biopharmaceutical CMO & CRO Market Size by Product & CAGR (2026-2033)

• Market Overview
• Biologics
  • Monoclonal antibodies (MAbs)
  • Recombinant Proteins
  • Vaccines
  • Antisense, RNAi, & Molecular Therapy
  • Others
• Biosimilars

Global Biopharmaceutical CMO & CRO Market Size & CAGR (2026-2033)

• North America (Source, Service Type, Product)
  • US
  • Canada
• Europe (Source, Service Type, Product)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Service Type, Product)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Service Type, Product)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Service Type, Product)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace Holdings (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PRA Health Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations